• 산경연구논집
• /
• 제6권4호
• /
• pp.23-26
• /
• 2015

Purpose - To mislead shareholders about a firm's actual economic performance, managers frequently manage dividends. Earnings management also affects performance reviews. Managers attempt to manage reported earnings caused by current economic events to accurately reflect their current performance. Research design, data, and methodology - The sample consisted of 312 company-years from companies in the pharmaceutical distribution industry listed on the Tehran Stock Exchange. A study period from 2004 to 2014 was selected. In this study, a model for measuring the performance of the net profits to total assets of a division of Jones was used to measure earnings management. Results - This study found a negative correlation between corporate performance and earnings management. Conclusions - The results for the earnings management company indicated a significant inverse relationship. Therefore, the company's performance weakened as its earnings management activity increased. In other words, the results showed that the company's performance-based accruals earnings management, the actual management of profits, and the general level of earnings management had significant inverse relationships. Thus, as the company's profits declined, earnings management activity increased.

• Archives of Pharmacal Research
• /
• 제21권4호
• /
• pp.418-422
• /
• 1998

Aim of this work is to prepare poly(DL-lactide-co-glycolide) (PLGA) nanoparticles by dialysis method without surfactant and to investigate drug loading capacity and drug release. The size of PLGA nanoparticles was 269.9 $\pm$118.7 nm in intensity average and the morphology of PLGA nanoparticies was spherical shape from the observation of SEM and TEM. In the effect of drug loading contents on the particle size distribution, PLGA nanoparticles were monomodal pattern with narrow size distribution in the empty and lower drug loading nanoparticles whereas bi- or trimodal pattern was showed in the higher drug loading ones. Release of clonazepam from PLGA nanoparticles with higher drug loading contents was slower than that with lower loading contents.

• 약학회지
• /
• 제56권2호
• /
• pp.116-125
• /
• 2012

Local pharmaceutical companies in Korea, which have grown focusing on domestic markets, have recently faced difficulties such as market saturation, price control policies and market-opening pressures by FTA. It seems to be an urgent issue for them to export pharmaceuticals to developed countries comprising the greater part of the global pharmaceutical market. Hence, this research was conducted to investigate and benchmark the strategies employed by India industry for the successful access to the global pharmaceutical markets. Drug policies as well as their influences on pharmaceutical market changes between India and Korea for the last 40 years have been searched and the differences have been comparatively analyzed. The pharmaceutical industry of India has the following strengths: low costs; experienced labor pool; excellent reverse-engineering skills; powerful IT; marketing capability; and established distribution network. After 2000, consolidations, M&A and alliances with domestic and multinational companies have been sharply increased in the industry of India. Indian companies unfolding both competition and cooperation with multinational corporations currently move up the value-added chain, and this enthusiastic strategy should be learned by local pharmaceutical companies.

• Nutrition Research and Practice
• /
• 제6권5호
• /
• pp.436-443
• /
• 2012

Previous Korean total diet studies (KTDSs) have estimated dietary exposure to toxic chemicals based on 110-120 representative foods selected from over 500 foods appeared in the Korea National Health & Nutrition Examination Surveys (KNHANES), which would result in a possible underestimation. In order to find measures for a closer-to-real estimate of dietary exposure to heavy metals, this study examined the feasibility of mapping foods to the representative foods in the KTDS by comparing estimates. In mapping, those foods not analyzed in the 2009 KTDS (443 out of 559 foods appeared in the 2007 KNHANES) were mapped to the 114 representative foods used in the 2009 KTDS based on the closeness in regards to biological systematics and morphological similarity. Dietary exposures to total mercury and lead were re-estimated using the content of total mercury and lead in 114 foods analyzed in the 2009 KTDS, food intake, and individual's own body weight for respondents in the 2007 KNHANES instead of mean body weight of Koreans used in the 2009 KTDS. The re-estimates of exposure with mapping were approximately 50% higher than the original estimates reported in the 2009 KTDS. In addition, mapping enabled the comparison of percentile distribution of the exposure among populations of different age groups. In conclusion, estimates via mapping resulted in a more comprehensive estimation of dietary exposure to heavy metals present in foods that Koreans consume.

• 대한환경공학회지
• /
• 제33권7호
• /
• pp.492-500
• /
• 2011

육상양식장에서 항생제에 대한 내성을 가진 균을 분리하여 다양한 항생제에 대한 내성특성을 확인하고, 전자빔의 조사에 따른 내성균의 항생제 내성 특성변화와 살균효능에 관한 연구를 수행하였다. 메기, 송어, 뱀장어, 미꾸라지양식장의 배출수에서 분리된 균주 중 Aeromonas sp., Citrobacter sp., Bacillus sp., Marinobacter sp., Pantoea sp., Pseudomonas sp., Enterobacter sp.가 다제내성균으로 확인되었다. 양식장 배출수에서 분리한 균주 중 한가지의 항생제 내성을 가지고 있는 균은 41.7%이며, 2가지 이상의 항생제 내성을 가지고 있는 균은 58.3%로 나타났다. Quantitative Structure Analysis Relationship (QSAR) model에 의한 평가는 실험값과 매우 유사하여 독성 평가의 간접적인 지표로 이용될 수 있음을 알 수 있었다. 항생제 내성균에 대해 전자빔을 조사한 결과 1 kGy 이내의 선량에서 살균효율이 99.9%로 강한 살균력을 확인할 수 있었다.

• 보건행정학회지
• /
• 제21권1호
• /
• pp.132-157
• /
• 2011

The purpose of this article is to examine the cause of policy non-compliance in the case of pharmaceutical rebates from the perspective of rational choice institutionalism. In Korea, there have been rebates practices between pharmaceutical companies and hospitals since the introduction of the Actual Remuneration System for insured medicine in 1999. The government has chosen the policy means of punishment to eliminate pharmaceutical rebates but the illegal practices are still widespread. Institution in rational choice institutionalism usually reflects the incentives and preferences of actors, and the Actual Remuneration System has resulted in a the lack of procedures to ensure savings on drug expenditures. Pharmaceutical rebates are the product of the institutions which reflect their incentives: the Actual Remuneration System, the current pricing policy for generic drugs, the drug distribution system, and so on. In the end, the problem of the rebates is the consequence of policy non-compliance as actors' rational choice because their incentives lead to opportunistic behaviors. We should therefore understand the incentive structure of policy stakeholders, which is derived from the view of new institutionalism; also, the newly designed Korean drug pricing policy reform must be compatible with the incentive structure.

• 한국임상약학회지
• /
• 제23권2호
• /
• pp.106-113
• /
• 2013

Background: For Korean pharmaceutical industry to continue to grow, it is requisite to enter the global markets of developed countries. However, the export volume has fallen short of 10% of the gross sales and the industry has only recently warming up to prepare the globalization along with suchlike the Columbus Project. Purpose: This research was conducted to identify the difficulties Korean pharmaceutical companies perceived and to discover the gap in the needs for the government aid the companies have been seeking in the purpose of entering the developed pharmaceutical markets. Method: A survey method was used for this research. Six experts were surveyed and provided comments for the pre-questionnaire. Then, a final questionnaire was developed consisting of 10 items on regulatory-related and another 10 items on non-regulatory-related factors in drug exportation using the Likert scale (1 to 5). The survey sample was 30 Korean companies which have participated in the Columbus Project since 2010. Results: Nineteen (63%) companies responded to the survey. Most companies perceived difficulty (mean = 4.19) over the entire pathway of the regulatory process of global markets. Clinical trials and post-marketing surveillance were remarked as the most difficult barrier to follow the regulatory globalization. Among non-regulatory related factors, marketing, arranging a distribution network, obtaining experts, and projecting a timeline in exportation were brought up as the most difficulty. Conclusion: Especially, cost and language barrier were considered as the main cause producing these difficulties across regulatory and non-regulatory processes and accordingly, securing both long term budget and experts at governmental level was suggested by the domestic pharmaceutical companies.

• 인터넷정보학회논문지
• /
• 제15권4호
• /
• pp.21-31
• /
• 2014

단백질 의약품 산업이 성장함에 따라 단백질 의약품 개발 시 단백질 정보는 필수적으로 인식 되고 있다. 단백질 정보 서비스를 제공하는 대표적인 바이오데이터 센터로는 미국의 NCBI, PDB, 유럽의 EMBL, 일본의 DDBJ 등이 있으며, 각 센터별로 특화된 단백질 정보들이 제공되고 있다. 사용자가 원하는 단백질 정보를 얻기 위해서는 독립된 단백질 정보를 검색하고 이를 통합하고 분석해야하며, 보다 편리하게 접근할 수 있도록 대표적인 데이터 센터 혹은 소규모 프로젝트 별로 바이오데이터에 대한 다양한 웹서비스가 연구 개발되고 있다. 단백질 의약품 정보 서비스에 대한 필요성이 높아지면서 캐나다의 DrugBank, 미국의 GDSC 등에서 의약품 정보와 단백질 데이터를 통합하여 서비스하고 있다. 하지만 사용자가 요구하는 다양한 단백질 정보를 반영하지 못하는 실정이다. 국내의 경우 바이오인포매틱스 인프라가 부족하고, 단백질 의약품 정보 서비스 또한 의약품의 기본 정보와 유통정보만을 제공하는 것에 한정되어 있다. 본 연구에서는 기존 서비스의 한계를 벗어난 한국형 단백질 의약품 전용 서비스 설계를 위한 사전 연구로 기존 대표적 데이터베이스에서는 적용하고 있지 않은 단백질 특성정보필드들을 제시하고 이에 대한 유용성 평가를 전문 종사자를 대상으로 진행하여 기존 바이오데이터베이스의 단백질 정보 필드와 비교하였다. 그 결과 본 연구에서 제시한 단백질 특성정보필드들이 단백질 의약품 정보 서비스에 요구되는 유용한 데이터 필드임을 검증하였다.

• 한국컴퓨터정보학회논문지
• /
• 제20권2호
• /
• pp.197-208
• /
• 2015

세계적으로 유통되고 있는 가짜의약품으로 인하여 제약사들은 판매수익과 기업브랜드 이미지에 큰 피해를 입고 있는 실정이고, 불법적으로 유통된 의약품이 복용 또는 투약된 환자(소비자)들은 생명에 위협을 받을 가능성이 점점 더 높아지고 있다. 이러한 가짜의약품의 유통을 근절시키기 위하여 세계 각국에서는 의약품의 생산에서부터 소비자에게 판매될 때까지 즉 의약품 유통과정을 추적하여 가시성있는 이력관리를 할 수 있도록 RFID 및 barcode 등 IT기반의 e-Pedigree(electronic pedigree)의 법제화 및 일련번호 관리제도를 도입하고 있다. 따라서, 본 연구에서는 국내 외 의약품 관리체계를 고찰하고 RFID 기반의 e-Pedigree 적용방안을 제시함으로써 국내 제약산업의 유통합리화와 이를 통한 소비자 안전성을 제고시키는데 그 목적이 있다.

• 한국항만경제학회지
• /
• 제34권3호
• /
• pp.1-16
• /
• 2018

고령화 사회 및 4차 산업혁명 이슈로 인하여 바이오의약품에 대한 수요가 증가하고 있다. 이에 전 세계적으로 바이오 의약품 산업규모가 지속적으로 증가하고 있으며, 바이오의약품 물류도 동반 성장하고 있다. 하지만 국내 의약품 유통구조는 선진국에 비해 낙후되어 있으며, 바이오 의약품취급에 대한 물류 규정이 엄격해지고 있어 체계적인 관리가 요구되고 있다. 이처럼 바이오 의약품 물류에 대한 철저한 관리의 필요성과 더불어 기업이 경영환경이 치열해 지면서 의약품 콜드체인 3자 물류업체의 역할의 중요성이 더욱 부각되고 있는 실정이다. 이에 본 연구에서는 의약품 콜드체인 3자 물류업체의 선택요인에 대한 연구를 수행하고자 하며 선택요인이 만족도에 미치는 영향력을 검증하여 중요한 선택요인을 파악하였다. 콜드체인 3자 물류 선정요인이 콜드체인 3자 물류 만족도에 어떠한 영향을 미치는지 알아보기 위하여 다중회귀분석을 실시하였는데 분석결과 전문성과 시설 및 연계성이 고객 만족도에 영향을 미치는 요인으로 나타났으며, 경영능력은 영향을 미치는 요인이 아닌 것으로 도출되었다. 이러한 연구 결과는 향후 의약품 콜드체인 산업이 나아가야할 방향성을 제시해 줄 수 있으며, 전략적 시사점을 제공할 수 있을 것으로 기대한다.